NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rauwolfia Serpentina is an oral tablet containing root extract from the Rauwolfia serpentina plant, a traditional herbal botanical with historical use in managing hypertension and related cardiovascular conditions. The product is in pre-launch development as an NDA with Bausch + Lomb as sponsor. Mechanism of action and specific indications are not currently documented in available regulatory filings.
Pre-Launch
Early-stage pre-launch product with undefined commercial trajectory; team size and resource allocation will depend on regulatory progression and sponsor commitment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Rauwolfia Serpentina offers opportunity to shape the launch of a botanical-based therapeutic in a pre-approval phase, with involvement in regulatory strategy, safety surveillance, and initial market positioning. Career impact depends entirely on NDA approval timeline and sponsor's commercial commitment post-launch.
Regulatory Affairs SpecialistClinical Trial Manager
Worked on RAUWOLFIA SERPENTINA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.